Mounjaro Alternatives & Comparison
Mounjaro (tirzepatide) set beside Ozempic, Trulicity, Rybelsus: how each works, what its trials measured, what it costs, and who sells it.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Mounjaro Alternatives Compared
For glycemic control, this is the head-to-head most people mean
Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels.
Neither drug carries a weight-loss label — both treat type 2 diabetes, and both get prescribed off-label for weight constantly. SURPASS-2 compared them directly: −11.2 kg on Mounjaro 15 mg against −5.7 kg on Ozempic 1 mg over 40 weeks, with a larger A1C drop too. Ozempic carries the completed cardiovascular result — MACE −26% in SUSTAIN-6. Retail pricing is close, near $1,000 either way, and neither has a real manufacturer cash-pay tier for weight loss.
Full Ozempic vs Mounjaro comparison →Weekly GLP-1 whose real-world record in type 2 diabetes runs longer than anything else here
Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing two modified GLP-1 peptide chains to a human IgG4 Fc fragment, which extends the half-life to about five days and allows once-weekly dosing.
Same manufacturer, successive generations. SURPASS-2 put Mounjaro 15 mg at −11.2 kg over 40 weeks against Trulicity 1.5 mg at −2.9 to −3.1 kg over 26 weeks. Trulicity has the completed cardiovascular result, REWIND's MACE −12%; Mounjaro's SURPASS-CVOT is pending 2027. Pricing is close — about $987 against $1,069 — with both savings cards restricted to commercial insurance. Trulicity's remaining case is the outcomes data and a step-therapy requirement that may put it first anyway.
Full Trulicity vs Mounjaro comparison →The daily-tablet route, for anyone ruling out injections
Rybelsus delivers semaglutide — a GLP-1 receptor agonist — in tablet form by co-formulating each pill with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that transiently raises gastric pH and helps the semaglutide peptide cross the gastric mucosa intact before stomach acid and proteases can degrade it.
Two diabetes drugs, neither approved for weight management, compared mostly by people who want the weight effect anyway. SURPASS-2 reported −11.2 kg at 40 weeks for Mounjaro; PIONEER 1 reported −4.4 kg at 26 weeks for Rybelsus. Different trials and different durations. Retail sits near $1,029 and $1,069, with Lilly's card requiring commercial insurance. The dosing burden is the honest differentiator: a daily fast, or a weekly injection.
Full Rybelsus vs Mounjaro comparison →Tirzepatide again, this time approved for chronic weight management
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects.
One molecule, one dose ladder, one maker, sold twice under two names. Diabetes sits on the Mounjaro label; obesity and sleep apnea sit on Zepbound's. Pricing is identical at $349 starter and $499 maintenance for vials. The practical difference is which label your prescription is written against, because that is what decides coverage. Nothing pharmacological separates them, and any page implying otherwise is selling something.
Full Zepbound vs Mounjaro comparison →Compare compounded Tirzepatide providers
Compounded tirzepatide sits at a middle figure of $258/month across 435 price points in the register, spanning $83 to $1,400. The partners below are ordered by our partner economics.
Compare compounded Semaglutide providers
Compounded semaglutide sits at a middle figure of $190/month across 481 price points in the register, spanning $65 to $1,585. The partners below are ordered by our partner economics.
Compare every Mounjaro provider
Current price, verification status, product form and the states each seller ships to, all on one screen.